Outline of JUA clinical guidelines for benign prostatic hyperplasia.
about
Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of actionRole of Acoustic Radiation Force Impulse (ARFI) Elastography in Determination of Severity of Benign Prostate Hyperplasia(-)Doxazosin is a necessary component for the hypotensive effect of (±)doxazosin during long-term administration in conscious ratsPostoperative infectious complications in our early experience with holmium laser enucleation of the prostate for benign prostatic hyperplasiaThe efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men.Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis.Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?A survey of the FAERS database concerning the adverse event profiles of α1-adrenoreceptor blockers for lower urinary tract symptoms.Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil.Comparison of outpatient versus inpatient transurethral prostate resection for benign prostatic hyperplasia: Comparative, prospective bi-centre study.Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report and review of the literature.Beta-Sitosterol: A Promising but Orphan Nutraceutical to Fight Against Cancer.Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.Relationship between Toe Temperature and Lower Urinary Tract Symptoms.The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin?The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study.A giant prostatic hyperplasia treated by open surgeryFunctional roles of bladder α1-adrenoceptors in the activation of single-unit primary bladder afferent activity in rats.Management of lower urinary tract symptoms associated with benign prostatic hyperplasia in elderly patients with a new diagnostic, therapeutic and care pathway.Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the manageClinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study compaAdd-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats.Percent decrease of serum prostate-specific antigen after dutasteride administration is equivalent in men with clinical benign prostatic hyperplasia having baseline prostate-specific antigen >10 ng/mL and those having baseline prostate-specific anti
P2860
Q26783529-957C75A0-0E6F-4A05-9B0B-997CF08ACA31Q30368343-88B705DA-265B-428E-A891-9322F07B7A26Q33823685-83ED5352-F672-4E26-B965-6ADB33661A92Q34633841-EF9FBC36-3E1E-4260-B586-9F5902489CB0Q36089975-EDB4628E-FEF7-4042-BFB6-AD7A359EB49BQ36245584-D6D277DE-9DD9-4B33-8821-81D1C72670F8Q36481250-5BAB7000-D1A9-4672-91BF-3E0892E698C7Q36909828-54870C78-2101-43CF-8001-268155448A8AQ37466573-4A909495-B097-4669-A712-086BCD27422CQ37496451-0BA5E980-76E6-4A37-9BA6-CD3908E54B72Q38186889-905B33D9-3200-4883-AACE-44C04D43F8BEQ38608961-9A44FC7A-1F47-4B12-AC18-D81198C818B0Q39176604-A4CD09B0-895C-4332-9388-A9418F1B39C6Q39242709-E5ADDBA7-DD28-46AB-B09E-02350794A755Q39427078-0A8FC638-B402-456B-BE96-1D0C09EDA2D7Q40215585-2EF4D36E-698E-44AD-B83D-A653ED9B7B3FQ41164717-30F4E0D6-EAB3-4C7A-BD93-EC673578CDBBQ41845111-F1B4F16D-5545-4F70-9750-37618634B7E3Q42481823-5958C176-7F06-45C7-82C8-0A681CD28A71Q43353576-A5A0C572-A97C-4890-98A1-20846FABDC40Q43902268-96EAB67A-C9EE-4036-929E-E685AF8D74BAQ47704193-8FADC259-459C-4EE4-A3ED-5827D447A5BCQ48563363-5AC1D52A-08E8-4EC5-9F12-2969B105856FQ48970211-5F5BC6C5-45CF-4ED2-B378-1187C6014D22Q49124632-BF8B23BB-C8F7-4040-8524-2067DF148104Q52612616-552203D1-8C9E-471F-BD9B-B87E2DC5A58EQ54714433-2F527F83-315F-4A77-B16F-52E65FB0FFE0
P2860
Outline of JUA clinical guidelines for benign prostatic hyperplasia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Outline of JUA clinical guidelines for benign prostatic hyperplasia.
@en
Outline of JUA clinical guidelines for benign prostatic hyperplasia.
@nl
type
label
Outline of JUA clinical guidelines for benign prostatic hyperplasia.
@en
Outline of JUA clinical guidelines for benign prostatic hyperplasia.
@nl
prefLabel
Outline of JUA clinical guidelines for benign prostatic hyperplasia.
@en
Outline of JUA clinical guidelines for benign prostatic hyperplasia.
@nl
P2093
P2860
P1476
Outline of JUA clinical guidelines for benign prostatic hyperplasia.
@en
P2093
Akihiro Kawauchi
Atsushi Nagai
Japanese Urological Association
Momokazu Gotoh
Naoya Masumori
Narihito Seki
Osamu Ishizuka
Osamu Yokoyama
Seiichiro Ozono
Tomonori Yamanishi
P2860
P304
P356
10.1111/J.1442-2042.2011.02860.X
P577
2011-11-01T00:00:00Z